BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
Conference call and webcast rescheduled for 8:30 a.m. Eastern Time on Monday, May 19
NEW YORK, May 15, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update.
"BrainStorm continues to make meaningful progress in advancing our NurOwn® development program. Our priority continues to be initiation of a Phase 3b trial, designed to confirm the product's efficacy in early stage ALS patients and support a new BLA," said Chaim Lebovits, President and Chief Executive Officer of BrainStorm. "We have a clear path forward and ongoing support from the ALS community. We recently submitted an amendment to our IND, which includes updated documentation that is essential for regulatory compliance and trial integrity. We are in the process of finalization clinical trial agreements with leading academic centers and completing other necessary steps on trial execution and manufacturing. We believe that NurOwn, if approved, has the potential to become a valuable treatment option for ALS patients. Our team is fully aligned and executing with discipline to position BrainStorm for success."
Recent Highlights
NurOwn (MSC-NTF) for ALS
IND amendment on NurOwn submitted to FDA BrainStorm submitted an Investigational New Drug (IND) amendment to the U.S. Food and Drug Administration for NurOwn. This important milestone sets the stage for the initiation of the planned Phase 3b clinical trial, which has been designed in collaboration with the FDA under a Special Protocol Assessment (SPA). The trial will have a primary efficacy endpoint assessing changes in ALSFRS-R scores from baseline to week 24, and is designed to enroll approximately 200 ALS participants with early stage disease. Successful completion of the double blind part of the study (Part A) is expected to generate the clinical data to support a new BLA submission.
Phase 3b trial listed on Clinicaltrials.gov. Details of the trial, known as ENDURANCE, are now available on ClinicalTrials.gov ID NCT06973629. Included is a list of 15 clinical trial sites that are expected to participate in the trial.
NurOwn® data selected as Breakthrough Science for Presentation at ISCT 2025 Meeting The new pharmacogenomic were delivered in a oral presentation at the International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting, in New Orleans. The data highlight the impact of the UNC13A genotype on clinical outcomes for ALS patients treated with NurOwn. The presentation was featured in the ISCT public announcement regarding the meeting, which indicated that the data were "carefully reviewed and selected by the ISCT 2025 Planning Faculty, to explore the latest breakthroughs in the clinical translation of Mesenchymal Stem/Stromal Cells and how they will shape the future of cell therapies."
Biomarker insights supporting NurOwn's mechanism and clinical impact presented at the 2025 ALS Drug Development Summit BrainStorm's senior leadership team (Dr. Bob Dagher, Dr. Netta Blondheim-Shraga and May Kay Turner) participated in sessions at the summit that highlighted insights and expertise gained throughout the NurOwn® development program. These sessions included a presentation on cerebrospinal fluid (CSF) biomarker pathways associated with NurOwn treatment, including their relationship to clinical outcomes and disease heterogeneity in ALS.
Financial Results for the First Quarter Ended March 31, 2025
Cash, cash equivalents, and restricted cash were approximately $1.8 million as of March 31, 2025.
Research and development expenditures, net, for the quarter ended March 31, 2025 were $1.3 million, compared to $1.0 million for the quarter ended March 31, 2024.
General and administrative expenses for the quarter ended March 31, 2025 were approximately $1.8 million, compared to approximately $1.5 million for the quarter ended March 31, 2024.
Net loss for the quarter ended March 31, 2025, was approximately $2.9 million, as compared to a net loss of approximately $3.4 million for the quarter ended March 31, 2024.
Net loss per share for the three months ended March 31, 2025, and 2024 was $0.45 and $0.75, respectively.
Conference Call and Webcast
Monday, May 19, 2025, at 8:30 a.m. U.S. Eastern Time
Participant Numbers:
U.S. dial in: 888-506-0062
International: 973-528-0011
Participant Access Code: 621608
Webcast URL: https://www.webcaster4.com/Webcast/Page/2354/52457
The replay of the conference call can be accessed by dialing the numbers below and will be available for 14 days.
Teleconference Replay Number:
Toll Free: 877-481-4010
International: 919-882-2331
Passcode: 52457
About NurOwn®
The NurOwn® technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells are designed to effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) is a leading developer of autologous adult stem cell therapies for debilitating neurodegenerative diseases. The company's proprietary NurOwn® platform uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), designed to deliver targeted biological signals that modulate neuroinflammation and promote neuroprotection. NurOwn® is BrainStorm's lead investigational therapy for amyotrophic lateral sclerosis (ALS) and has received Orphan Drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). A Phase 3 trial in ALS (NCT03280056) has been completed, and a second Phase 3b trial is set to launch under a Special Protocol Assessment (SPA) agreement with the FDA. The NurOwn clinical program has generated valuable insights into ALS disease biology, including pharmacogenomic response associated with the UNC13A genotype, biomarker data collected at seven longitudinal time points, and a comprehensive analysis of the "Floor Effect" — a critical challenge in measuring clinical outcomes in advanced ALS. BrainStorm has published its findings in multiple peer-reviewed journals. In addition to ALS, BrainStorm has completed a Phase 2 open-label multicenter trial (NCT03799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, further strengthening BrainStorm's growing IP portfolio in this emerging area of regenerative medicine. To learn more, visit www.brainstorm-cell.com.
Notice Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties, including statements regarding meetings with the U.S. Food and Drug Administration (FDA), Special Protocol Assessment (SPA), the clinical development of NurOwn as a therapy for the treatment of ALS, the future availability of NurOwn to patients, and the future success of BrainStorm. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BrainStorm's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. These potential risks and uncertainties include, without limitation, management's ability to successfully achieve its goals, BrainStorm's ability to raise additional capital, BrainStorm's ability to continue as a going concern, prospects for future regulatory approval of NurOwn, whether BrainStorm's future interactions with the FDA will have productive outcomes, and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.
CONTACTSInvestors:Michael WoodPhone: +1 646-597-6983mwood@lifesciadvisors.com
Media:
Uri Yablonka, Chief Business OfficerPhone: +1 917-284-2911uri@brainstorm-cell.com
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIES
INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS
U.S. dollars in thousands
(Except share data)March 31,December 31,
20252024
UnauditedAudited
U.S. $ in thousands
ASSETSCurrent Assets:
Cash and cash equivalents$
1,644$
187
Other accounts receivable
67
63
Prepaid expenses and other current assets
621
135
Total current assets$
2,332$
385Long-Term Assets:
Prepaid expenses and other long-term assets $
22$
22
Restricted Cash
182
184
Operating lease right of use asset (Note 4)
653
807
Property and Equipment, Net
382
434
Total Long-Term Assets$
1,239$
1,447Total assets$
3,571$
1,832LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)Current Liabilities:
Accounts payables$
6,797$
6,080
Accrued expenses
538
619
Short-term loans (Note 7)
1,200
300
Operating lease liability (Note 4)
443
549
Employees related liability
1,923
1,430
Total current liabilities$
10,901$
8,978Long-Term Liabilities:
Operating lease liability (Note 4)
127
171
Warrants liability (Note 5)
-
447
Total long-term liabilities$
127$
618Total liabilities$
11,028$
9,596Stockholders' Deficit:
Stock capital: (Note 6)
15
14
Common Stock of $0.00005 par value - Authorized: 250,000,000 shares at March 31, 2025 and at December 31, 2024 respectively; Issued and outstanding: 7,911,204 and 6,141,762 shares at March31, 2025 and December 31, 2024 respectively (*)
Additional paid-in-capital
222,144
218,974
Treasury stocks
(116)
(116)
Accumulated deficit
(229,500)
(226,636)
Total stockholders' deficit$
(7,457)$
(7,764)Total liabilities and stockholders' deficit$
3,571$
1,832
The accompanying notes are an integral part of the consolidated financial statements.
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIES
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)
U.S. dollars in thousands
(Except share data)
Three months ended March 31, 20252024Unaudited
Operating expenses:Research and development, net
$
1,304$
961
General and administrative1,785
1,513
Operating loss(3,089)
(2,474)
Financial income, net46
13
Loss on change in fair value of Warrants liability (Note 6)(179)
(940)
Net loss
$
(2,864)$
(3,401)
Basic and diluted net loss per share from continuing operations
$
(0.45)$
(*) (0.75)
Weighted average number of shares outstanding used in computing basic and diluted net loss per share6,342,002
(*) 4,315,903
The accompanying notes are an integral part of the consolidated financial statements.
Logo: https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-announces-first-quarter-2025-financial-results-and-provides-corporate-update-302456908.html
SOURCE BrainStorm Cell Therapeutics Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Chicago Tribune
27 minutes ago
- Chicago Tribune
Jim Taylor: What my wife's experience with Alzheimer's has taught me
After several unexplained memory slips, there came a day when my wife, Geri, didn't recognize her own face in the mirror. That's when we knew it was time for her to get checked out. It was 2012, and Alzheimer's was a feared diagnosis. At the time, billions of dollars of investments into research and development had failed to produce treatments that could prevent, slow or cure the disease. Getting a definitive diagnosis would be extremely difficult, but the alternative was living with years of the landscape for Alzheimer's diagnosis and treatment has taken a great leap forward. It is increasingly possible to manage the disease and live a fulfilling life. We have reached a historic moment with the FDA's approval of the first blood biomarker tests for Alzheimer's. This long-awaited breakthrough means physicians can now detect early signs of Alzheimer's — which accounts for 70% of all cases of dementia — using a simple blood test that can be done during a regular check-up with your PET scans remain important for confirming a diagnosis, they are only available at specialized centers, typically in urban medical centers, and they are expensive. Blood biomarker tests now offer an easy first step in the diagnostic journey. They provide fast answers for people experiencing memory problems and can even spot early signs of cognitive decline years before symptoms appear. Without these tests, most people have a long, challenging path to wife Geri's path to diagnosis was anything but simple. In 2012, a neurologist confirmed she had mild cognitive impairment, a common precursor to Alzheimer's. It was a life-altering event. Over the next few years, we knew we had to dig deeper into the cause of her condition, to uncover any potential medical options. Eventually we found a clinical trial for an experimental Alzheimer's drug, and she received a PET scan to determine whether she qualified for the trial. Her brain scan detected amyloid plaque, the telltale sign of Alzheimer's. The diagnosis was difficult to face, but it meant we didn't have to struggle with uncertainty. We could act.I understand the fear that surrounds an Alzheimer's diagnosis, but catching it early helps. Changes in the brain begin years before memory problems become noticeable. The earlier the diagnosis, the more options people have. Research shows that anti-amyloid therapies are more effective when administered earlier: In one clinical trial, patients with early Alzheimer's showed 35% slowing of cognitive decline, compared with those on the placebo. These treatments can help people maintain their independence longer and make the most of their lucid was fortunate to participate in a clinical trial that significantly slowed her disease progression. The seven-year trial period was a game-changer for us. The regular infusions were a source of hope as we saw her benefit from the medication. This precious time allowed Geri to develop coping strategies to manage her disease. Together, we traveled across the country giving talks about living with Alzheimer's disease, and Geri needed very little assistance. We cherished this time together — years made possible because we sought answers early. Following the FDA's landmark approval of blood biomarker tests, the next step is making these tests widely available. Hospitals and health care systems across the country should ensure primary care physicians are aware of these tests and understand how to use them. Public education campaigns can raise awareness with people who have concerns about cognitive impairment and their detection gives people meaningful choices, and most importantly it gives people time. Time to benefit from lifestyle changes, participate in groundbreaking clinical trials, and access treatments when they can make the greatest difference. Although facing a potential Alzheimer's diagnosis is daunting, waiting only limits a person's options. If you're concerned that you or a loved one might have signs of cognitive impairment, please don't stay in the dark. Blood biomarker tests offer real hope in a new era of Alzheimer's care. The sooner we embrace these advances, the more precious time we can preserve.
Newsweek
3 hours ago
- Newsweek
Dr Pepper Recall Issued After Sugar Mix Up in Thousands of Cans
A recall has been issued for thousands of cases of Dr Pepper Zero Sugar that were mislabeled and contained the full-sugar product, according to the U.S. Food and Drug Administration (FDA). The products were distributed to retailers in Florida, Georgia, and South Carolina. Newsweek contacted Keurig Dr Pepper, which owns the product in the United States, and PepsiCo, which bottled the beverages, for comment via email outside of regular working hours. Why It Matters This mislabeling poses potential health risks to consumers, particularly for individuals managing conditions like diabetes or those monitoring their sugar intake The FDA has issued a Class II risk classification for the recall, indicating that the consumption of the mislabeled products may cause temporary or medically reversible adverse health consequences. What To Know The FDA said the company-initiated recall affects 19,203 cases of Dr Pepper Zero Sugar 12-fluid ounce cans, sold in 12-pack and 24-pack cartons. The affected cans were produced at a Pepsi bottling facility in Jacksonville, Florida, which is licensed to manufacture Keurig Dr Pepper products, according to the FDA. The affected products have the product code XXXXRS05165, and a best-by date of February 16, 2026. The recall was initiated on May 23, 2025, and the FDA classified it as a Class II recall on June 5, 2025. A can of regular Dr Pepper contains 39 grams of sugar, while the Zero Sugar version has zero grams, but contains the artificial sweeteners aspartame and acesulfame potassium. There were 241 FDA food and beverage recalls in 2024, which was an increase of eight percent from the previous year, according to a report published by the nonprofit Public Interest Research Group. Undeclared allergens or ingredients was the single biggest cause for recalls that year. Last year, Dr Pepper tied with Pepsi to become the second most popular soda in the U.S. after Coca Cola, according to data from Beverage Digest. What Happens Next The FDA and Dr Pepper are working to ensure that all affected products are removed from store shelves promptly. Consumers in the affected states should remain vigilant and check their purchases to ensure they have not bought the mislabeled product.
Yahoo
5 hours ago
- Yahoo
ALS Walk raises over $100k
(WHTM) — Dozens came out to Hershey for the 2025 ALS Walk on Saturday. It was held at the Hershey Middle School on Homestead Road. The walk raises money to help fight the disease. Download the abc27 News+ app on your Roku, Amazon Fire TV Stick, and Apple TV devices Over $100,000 was collected. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
